# Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma

> **NCT05004025** · PHASE1 · COMPLETED · sponsor: **HonorHealth Research Institute** · enrollment: 10 (actual)

## Conditions studied

- Uveal Melanoma

## Interventions

- **DEVICE:** Novocure Optune
- **DRUG:** Opdivo
- **DRUG:** Yervoy

## Key facts

- **NCT ID:** NCT05004025
- **Lead sponsor:** HonorHealth Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-28
- **Primary completion:** 2024-11-18
- **Final completion:** 2025-07-23
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-08-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05004025

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05004025, "Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05004025. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*